DAONIL

This brand name is authorized in Australia, Brazil, Cyprus, Spain, France, New Zealand, Tunisia

Active ingredients

The drug DAONIL contains one active pharmaceutical ingredient (API):

1 Glibenclamide UNII SX6K58TVWC - GLYBURIDE

Glibenclamide, a second-generation, short half-life sulphonylurea, is a hypoglycaemic agent that reduces blood-glucose by stimulating insulin release by the pancreas. Sulphonylureas act on pancreatic beta-cells by inhibiting ATP-sensitive potassium channels. Read about Glibenclamide

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
A10BB01	Glibenclamide	A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10B Blood glucose lowering drugs, excl. insulins → A10BB Sulfonamides, urea derivatives
Discover more medicines within A10BB01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 2939Q
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 576720080083617
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 48545
Country: FR	Base de données publique des médicaments	Identifier(s): 64823509
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 1192
Country: TN	Direction de la Pharmacie et du Médicament	Identifier(s): 9103211A, 9103211B, 9263341, 9263342